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In Brief
Microtubule-inhibiting small molecules
are crucial for cell biology research and in
cancer therapy. Photostatins are
microtubule inhibitors that can be
switched on and off in vivo by visible light,
modulating microtubule dynamics with
subsecond response time, and
controlling mitosis with single-cell spatial
precision. Photostatins are also 250 times
more cytotoxic under blue light thanwhen
kept in the dark, making them both
valuable tools for cell biology, and
promising as precision-targeted
chemotherapeutics.
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Small molecules that interfere with microtubule
dynamics, such as Taxol and the Vinca alkaloids,
are widely used in cell biology research and as clin-
ical anticancer drugs. However, their activity cannot
be restricted to specific target cells, which also
causes severe side effects in chemotherapy. Here,
we introduce the photostatins, inhibitors that can
be switched on and off in vivo by visible light, to opti-
cally control microtubule dynamics. Photostatins
modulate microtubule dynamics with a subsecond
response time and control mitosis in living organisms
with single-cell spatial precision. In longer-term ap-
plications in cell culture, photostatins are up to 250
times more cytotoxic when switched on with blue
light than when kept in the dark. Therefore, photosta-
tins are both valuable tools for cell biology, and are
promising as a new class of precision chemothera-
peutics whose toxicity may be spatiotemporally con-
strained using light.INTRODUCTION
Microtubules (MTs) are highly dynamic components of the cyto-
skeleton that play vital roles in a variety of cellular processes,
including intracellular transport, cell motility, and proliferation
(Dumontet and Jordan, 2010). As such, small molecule inhibitors
that interfere with MT dynamics are indispensible tools in cell
biology (Peterson and Mitchison, 2002). In medicine, they are
one of the most clinically useful classes of chemotherapeutics,
due to their antimitotic and pro-apoptotic effects (Jordan et al.,
1998). However, the current inhibitors are nonspecific in the
sense that their bioactivity cannot be either spatially or tempo-
rally directed, e.g., against selected cells and tissues, at defined
times. This restricts their scope of application in research, as it
prevents their use in spatially or temporally addressing the varied
processes dependent on microtubule dynamics. In cancer med-
icine, this nonspecificity causes severe systemic side effects
such as cardiotoxicity and neurotoxicity (Ghinet et al., 2013;Hooper et al., 2013; Tozer et al., 2002; Tron et al., 2006), which
limit the doses at which chemotherapeutics can be applied,
thus impairing their therapeutic value (Dumontet and Jordan,
2010; Gill et al., 2014; Stanton et al., 2011). Therefore, devel-
oping inhibitors of MT dynamics whose action can be targeted
to specific cells at defined times is an important challenge (Ve-
lema et al., 2014).
Optically controlling MT inhibitors could be an elegant solution
to this problem of specificity, since light can be applied with high
spatiotemporal precision (Velema et al., 2014). Small molecule
approaches are particularly attractive, since genetic engineering
is not required and dosing is straightforward, so their scope for
practical applications to both research and medicine is exten-
sive. Prior research toward the optical modulation of MT inhibi-
tors has explored both photobleachable and photouncageable
drugs (Hadfield et al., 2002; Hamaguchi and Hiramoto, 1986;
Velema et al., 2014; Wu¨hr et al., 2010), and a photoactivation
approach based on carbon-carbon double bond isomerization
has been proposed (Bisby et al., 2013; Hadfield et al., 2002).
However, the nonspecific toxicity of these designsmay be signif-
icant, since short wavelengths and/or high light intensity are
required, leading to side reactions and toxic byproducts (Wu
et al., 2009). Fundamentally though, such irreversibly triggered
approaches cannot combat the diffusion of the active drug, so
they will always suffer from limited spatiotemporal resolution.
Spatially and temporally restricting bioactivity instead demands
reversible, in situ switching over many off4on cycles (Velema
et al., 2014). We here present a series of MT inhibitors that can
be fully reversibly photoswitched by low-intensity visible light,
to control microtubule structure, dynamics, and a range of MT-
dependent processes in living cells and organisms, with the
spatiotemporal precision of light.RESULTS
Design and Photoswitching of Photostatins
We designed the photostatins (PSTs) as reversibly photoswitch-
able analogs of combretastatin A-4 (CA4) (Pettit et al., 1989).
CA4 is one of the most prominent colchicine domain MT inhibi-
tors (CDIs). Its potency, its vascular disrupting and antiangio-
genic properties, and its avoidance of multidrug-resistance
make it a promising candidate for tumor chemotherapy, andCell 162, 403–411, July 16, 2015 ª2015 Elsevier Inc. 403
AB
C D
Figure 1. Design, Synthesis and Switching of the Photostatins
(A) Structural comparison of PSTs with colchicine and CA4 (the pharmaco-
phore is indicated in blue).
(B) Synthesis and switching of representative compound PST-1: only the cis
isomer displays the CDI pharmacophore.
(C) PST prodrugs that are unmasked by enzymes.
(D) PST-1 is rapidly and reversibly photoswitched, with excellent photo-
stability, by alternating 388 nm (violet) and 508 nm (green) illuminations (plot:
absorbance at 378 nm, in PBS; see also Figures S1A and S1B).three CA4 derivatives have progressed to clinical trials (Tozer
et al., 2002; Tron et al., 2006). The CA4 pharmacophore is a
trimethoxybenzene ring held cis to a low-steric-demand,
methoxy-bearing arene (Bhattacharyya et al., 2008). Crucially,
trans-CA4 is several orders of magnitude less potent than the
cis isomer (Tron et al., 2006). We replaced the bridging C=C
double bond of the stilbenoid combretastatins with an isosteric
N=N double bond to give the azobenzene PSTs, which can be
trans4cis photoisomerized with full reversibility and excellent
photostability over many cycles by low intensity visible light (Fig-
ure 1). We anticipated that the cis-PSTs would reproduce the
valuable pharmacology of CA4, while their trans isomers would
be biologically inactive. We aimed to reversibly photoswitch
PSTs between the cis and trans isomeric forms in situ, to turn
their bioactivity on and off, with high spatiotemporal precision,
inside living cells and organisms.
We synthesized a series of PSTs (PST-1–PST-5) by diazonium
coupling, in two to four synthetic steps (Figure 1 and Supple-
mental Information) (Thorn-Seshold et al., 2014). Considering
the solubility problems that have hampered the combretastatins,
we also prepared PST-1P and PST-2S, as azobenzene analogs
(‘‘azologues’’) of two nonspecific combretastatin prodrugs that
have entered Phase III clinical trials: PST-1P is an azologue
of CA4 phosphate (known as CA4P or ‘‘fosbretabulin’’) and404 Cell 162, 403–411, July 16, 2015 ª2015 Elsevier Inc.PST-2S is an azologue of the serinyl anilide ‘‘ombrabulin’’ (Oh-
sumi et al., 1998; Pettit and Rhodes, 2009). Lastly, PST-1CL
was synthesized to explore dual optical-and-biochemical target-
ing via exopeptidases (Thorn-Seshold et al., 2012).
The switching of the PSTs was demonstrated by UV-Vis spec-
troscopy (Figure 1D and Supplemental Information, Part B). All
compounds were rapidly and fully reversibly photoswitched in
phosphate-buffered saline (PBS) buffer, without degradation
overhundredsofcycles,by low-power illumination. Theirpara-me-
thoxy substituents enable PSTs to be trans4cis photoswitched
using visible light (Knoll, 2003), benefiting in vivo compatibility:
380–420 nm light gives approximately 90% cis isomer, which
bears the CDI pharmacophore; longer wavelengths give
decreasing cis percentages until 500–530 nmgives approximately
85% trans isomer, which does not bear the pharmacophore (Fig-
ure S1A). In the dark, spontaneous (unidirectional) cis/trans
isomerization leads to 100% trans isomer, with half-lives t, ranging
from 0.8–120 min (Figure S1B), being modulated by the substitu-
tionpattern (Knoll, 2003).Thisprocessactsasasafetymechanism,
whereby the concentration of bioactive cis isomer will drop to zero
unless blue light pulsesare reapplied on the timescale of this rever-
sion half-life. Therefore, even without using green light to actively
switch off the PSTs, any cis-PST diffusing into a non-illuminated
area, or remaining after a period of illumination, will spontaneously
and rapidly be isomerized to trans, thus spatiotemporally restrict-
ing the PSTs’ inhibitory bioactivity to illuminated zones only.
TheToxicity of PSTsDepends on IlluminationConditions
The potency, robustness, and light-specificity of the PSTs’ bio-
logical effects were directly assessed in cellulo. Trans-PSTs
were assayed by shielding experiments from light (100% trans;
‘‘dark regime’’), while cis-PSTs were assayed by applying a
‘‘toxic regime’’ of frequently pulsed, short illuminations (e.g.,
75 ms pulses of 390 nm light every 15 s). To apply these illumi-
nations in cell culture, we hand-built a cheap, computerized
LED lighting system to illuminate > 30 well plates separately
with independent wavelengths and timings (Figure S6 and
Supplemental Information). Crystal violet assays in the MDA-
MB-231 human breast cancer cell line showed that PSTs
are powerfully cytotoxic under the toxic lighting regime, but
not in the dark. Their EC50 values of 0.5–5.4 mM under the toxic
regime represent potencies up to 100 times greater than under
the dark regime (Figures 2A and 2B and Figures S2A–S2I),
and closely similar results were obtained for the PSTs’ light-
dependent cytotoxicity in HeLa (cervical cancer) cells (Figures
S2J–S2N).
We then investigated the dependency of the PSTs’ bioactivity
on the irradiating wavelength in detail. We examined the prolifer-
ation of HeLa cells exposed to PST-1P, after pulsed illuminations
at a range of wavelengths from 370–535 nm, by MTT assay (Fig-
ures 2C and 2D). Illumination at 380–390 nm gave the most
potent cytotoxicity, while the dose-response curves for wave-
lengths up to 525 nm were translated progressively higher con-
centrations by factors that match the relative trans/cis ratios at
those wavelengths (Figure S1C). This supports the conclusions
that the choice of illuminating wavelength determines the con-
centration of the cis form generated, and that this cis concentra-
tion is the primary determinant of the PSTs’ bioactivity. For
-8 -7 -6 -5 -4
25
50
75
100
Log10 concentration (M)
v
ia
bl
e
ce
lls
(%
co
n
tr
ol
)
dark
390 nm
PST-1
-7 -6 -5 -4
0
25
50
75
100
Log10 concentration (M)
v
ia
bl
e
ce
lls
(%
co
n
tr
ol
) 390
410
450
475
490
525
535
PST-1P
dark
(nm)
A B
Compound EC50 dark EC50 390 nm
PST-1 38 µM 0.5 µM
PST-2 25 µM 0.5 µM
PST-3 35 µM 2.1 µM
PST-4 43 µM 1.4 µM
PST-5 37 µM 1.0 µM
PST-1P 71 µM 0.7 µM
PST-2S ND 5.4 µM
PST-1CL ND 4.2 µM
CA4P 4 nM -
C D
 (nm) EC50 ( M)
370 0.97
380 0.70
390 0.75
400 0.91
410 0.93
435 0.98
450 1.2
465 1.5
475 1.7
490 2.6
505 2.6
515 3.0
525 5.6
535 32
dark > 200
Figure 2. PSTs Are Submicromolar Cyto-
toxins when Irradiated with 390 nm Light,
but Even >250 Times Less Toxic in the Dark
(A) Cell viability dose-response curves for PST-1
under 390 nm irradiation and in the dark are
separated by approximately 2 orders of magnitude
(crystal violet staining, MDA-MB-231 cells, co-
solvents used).
(B) PSTs are between 20- to 100-fold more cyto-
toxic under 390 nm illuminations than in the dark
(same data as in A; see also Figures S2A–S2I).
(C) The cytotoxicity of PST-1P can be tuned by
choosing the wavelength of light applied (MTT
assay, HeLa cells, no cosolvents used).
(D) Dose-response curves for PST-1P are hori-
zontally translated according to the irradiating
wavelength used (same data as in C; see also
Figure S1C).
Results are given as mean ± SD.comparison, the trans isomer (assayed under dark conditions)
was confirmed to be > 250 times less toxic than the cis form,
and also showed a markedly shallower dose-dependency that
could argue for a different biochemical mechanism of toxicity
(Figure 2D, Figure S1C, and Supplemental Information, Part
C1). These experiments indicate how the PSTs’ biological effects
can be not only sharply controlled (illuminated or dark), but also
finely tuned (wavelength dependence) by lighting conditions.
PSTs Induce Mitotic Arrest and Cell Death in a
Light-Dependent Manner
We pursued further studies of the mechanism and light-depen-
dency of PST-induced cytotoxicity focusing on PST-1 and its
prodrug PST-1P. We first assayed cell membrane permeability
(propidium iodide exclusion assay) and nuclear fragmentation
(quantification of DNA content) in MDA-MB-231 cells. Neither
assay showed a response to PST-1 below 50 mM in the dark
regime. However, under the toxic regime, even submicromolar
PST-1 induced loss of membrane integrity, and depletion of
nuclear DNA content resulting in the emergence of hypodip-
loid (sub-G1) cells (Figures 3A and 3B and Figure S3E). Similar
results were obtained in Jurkat (T cell lymphoma) and HeLa
cells (Figures S3A–S3D). We subsequently examined cleavage
of poly(ADP-ribose) polymerase (PARP). Full-length PARP
(116 kDa) is involved in the repair of DNA damage caused by a
variety of cellular stresses. During apoptosis, PARP is cleaved
by caspase-3, caspase-7, and possibly by other suicidal prote-
ases, into an 89-kDa catalytic fragment and a 24-kDa DNA-
binding domain (Chaitanya et al., 2010). HeLa cells treated withCell 162, 403–PST-1P were analyzed by western blot
and showed the PARP proteolytic signa-
ture typical of apoptosis only under the
toxic lighting regime (Figure 3C).
Finally, cell-cycle analysis of MDA-
MB-231 cells treated with PST-1 showed
G2/M phase arrest beginning sharply
around 500 nM under the toxic regime
(Figures 3D and 3E), matching the EC50
values seen in the cytotoxicity assays. By contrast, in the dark
even 100 mMof PST-1 had no effect on cell-cycle repartition (Fig-
ures S3F and S3G). As G2/M arrest is typical of MT-disrupting
agents (Tron et al., 2006), this supports the design conjecture
that only cis-PSTs inhibit MT dynamics. Similar results were ob-
tained in HEK293T (human embryonic kidney) and HeLa cells
(Figures S3I and S3J). We also explored a dual wavelength
‘‘rescue protocol,’’ to illustrate repeated, dynamic photocontrol
over PST cytotoxicity. In this protocol, each pulse contains a
component at 390 nm immediately followed by another at
515 nm (so that the transiently formed cis is reisomerized back
to trans during each pulse). The rescue substantially reduced
G2/M arrest compared to the toxic regime (Figure S3H). This
highlights that PSTs can be reversibly and efficiently photoiso-
merized in cellulo in the long term (>5,000 trans/cis/trans
photoswitching cycles over 2 days), without degradation of the
drug and without phototoxicity to the cell.
Taken together, these results support the interpretation that
the cis-PSTs generated in situ upon blue light exposure potently
induce mitotic arrest, presumably linked to the activation of the
spindle assembly checkpoint, and result in cell death which
displays many characteristics of apoptosis. By contrast, the
trans-PSTs that are established under dark conditions (or which
predominate under longer wavelength illumination) are all but
inactive due to their 100-fold weaker cytotoxicity, which addi-
tionally does not involve mitotic arrest. Both these results are
general across a range of cell lines, supporting the conjecture
that PSTs should be appropriate for use in any eukaryotic sys-
tem. These experiments thereby supported our overall design,411, July 16, 2015 ª2015 Elsevier Inc. 405
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Figure 3. PSTs Induce Cell-Cycle Arrest and
Apoptosis upon Blue Light Illumination, but
Not in the Dark
(A) PST-1 gives light-dependent induction of
membrane permeability (propidium iodide exclu-
sion assay, MDA-MB-231 cells).
(B) PST-1 gives light-dependent induction of
nuclear fragmentation (increase of sub-G1 popu-
lation; MDA-MB-231 cells).
(C) Treatment with PST-1P results in PARP
cleavage upon blue light illumination, but not in the
dark (western blot, HeLa cells).
(D) MDA-MB-231 cells treated with 2 mM PST-1
show normal cell-cycle repartition in the dark (left)
while illumination under the toxic regime gives
strong G2/M arrest (right).
(E) PST-1 causes dose-dependent cell-cycle
arrest in G2/M phase under the toxic illumination
regime.
Results are given as mean ± SD. See Figure S3 for
further results.showing that PSTs can be used as antimitotic cytotoxins that can
be robustly and reversibly photoswitched in living cells between
the essentially ‘‘off’’ trans form and the potent ‘‘on’’ cis form. We
now turned our focus to testing the specific molecular premise
of the PSTs’ design: by evaluating their capacity to effect MT
disruption in situ in a reversibly photoswitchable manner.
PSTs Bind Tubulin and Inhibit Its Polymerization in a
Light-Controlled Manner
To validate tubulin as the molecular target of cis-PSTs, we first
assayed the ability of PST-1 to bind to the colchicine domain
on tubulin.We used purified tubulin in an in vitro radioligand scin-
tillation proximity assay (SPA) (Tahir et al., 2000) to examine
the competitive displacement of 3H-colchicine from its tubulin
binding site by PST-1 under light and dark conditions. This
assay confirmed that cis-PST-1 competes dose dependently
with colchicine for tubulin binding, as does its isosteric parent
drug CA4 (Figure 4A). The SPA returned an EC50 value of
30 mM for PST-1 under 390 nm illumination, with the reference
compound CA4 showing higher affinity (EC50 = 0.16 mM), which
mirrors the activity difference shown previously in the cytotox-
icity assays. Importantly, trans-PST-1 showed no significant
competitive binding to tubulin, further supporting the off4on
design conjecture of our study.
We next assayed PST-1 for inhibition of tubulin polymerization
in a biochemical assay using purified tubulin. PST-1 strongly406 Cell 162, 403–411, July 16, 2015 ª2015 Elsevier Inc.inhibited in vitro tubulin polymerization
under 390 nm illumination in a dose-
dependent manner (EC50 5 mM), but ex-
erted no inhibitory effects in the dark
(EC50 >> 40 mM; Figure 4B). Lastly, we
confirmed PST-1’s functional potency as
photoswitchable MT inhibitor in live cells
by immunofluorescence imaging of
endogenous tubulin. In the dark, PST-1
had no effects on MT structure, but underthe toxic regime PST-1 caused dose-dependent MT depolymer-
ization, as well as nuclear fragmentation that is typical of
apoptotic cells, as seen with the reference compound CA4 (Fig-
ure 4C, Figure S4A). This indicates that cis-PST-1 is a powerful
inhibitor of tubulin polymerization both in vitro and in cellulo,
while trans-PST-1 is not.
PSTs Achieve Reversible Optical Control over
Microtubule Dynamics in Live Cells
To directly visualize PSTs’ effects on MT dynamics in live cells,
we imaged the end-binding protein EB3. EB3 clusters at the
plus tips of growing MTs, and dissociates in phases of MT
shrinkage. As its binding/unbinding kinetics are fast, EB3 imag-
ing thus revealsMT growth dynamics (Bieling et al., 2007;Maurer
et al., 2012). We treated interphase cells expressing mCherry-
tagged EB3 with PST-1, and imaged them while photoswitching
PST-1 in situ with alternating 2min phases of pulsed 405 nm and
514 nm illuminations. Control cells (without PST-1 treatment)
showed no variation of comet behavior with the illumination
phase. In contrast, under PST-1 treatment, applying 405 nm light
led to the disappearance of EB3 comets in less than a second,
while changing to a 514 nm phase restored comet size and dy-
namics—also in less than a second—and this switching was
entirely reversible over many cycles (Movies S1 and S2;
Figure 5A; see also Supplemental Information). We used the
MATLAB software u-track (Applegate et al., 2011) to identify,
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Figure 4. cis-PST-1 Binds at the Colchicine
Site on Tubulin Heterodimers and Inhibits
Tubulin Polymerization In Vitro and In
Cellulo
(A) PST-1 exposed to 390 nm competes with
colchicine for tubulin binding, mirroring the effect
of the CA4 positive control, while no such inter-
action can be detected in the dark (radioligand
binding assay). Results are given as mean ± SD.
(B) PST-1 shows strong, dose-dependent inhibi-
tion of tubulin polymerization under 390 nm illu-
mination (violet curves), but in the dark even
40 mM PST-1 (black curve) shows near-identical
behavior to the negative control (gray curve)
(turbidimetric in vitro polymerization assay; greater
absorbance corresponds to a greater degree of
polymerization).
(C) Under the toxic regime, PST-1 induces MT
breakdown and nuclear fragmentation dose-
dependently, while under the dark regime, MT
structure is unaffected (MDA-MB-231 cells treated
for 20 hr with PST-1, then stained for a-tubulin
(green) and DNA (blue); scale bars, 20 mm; see also
Figure S4A).follow, and quantify the EB3 comets from several independent
movies (Movie S3), conservatively analyzing for the total number
of EB3 comets, aswell as their lifetime, speed, and distance trav-
eled. The combined statistics show that trans4cis photoisome-
rizations of PST-1 inside living cells achieve optical switching
of these functional parameters of MT polymerization dynamics,
thus allowing fully reversible switching between phases of ordi-
nary MT dynamics and of MT catastrophe simply by applying
light (Figures 5B–5E). Together with the preceding results, these
experiments indicate that PSTs are a robust and powerful tool
for precise, rapid, reversible, and noninvasive optical control
over both MT dynamics and MT-dependent processes, suitable
for both short- and long-term use in a range of systems from
in vitro to in cellulo.
PSTs Control Mitosis and the Microtubule Cytoskeleton
In Vivo
We next examined PST-1’s optical control over MT dynamics
in vivo. We monitored mitotic progression of developing
C. elegans embryo as a readout of functional microtubule
dynamics. The synchronicity of several blastomeres at early
developmental stages gives a useful internal control for the
normal mitosis rate (Strome and Wood, 1983). We used trans-
genic embryos with mCherry-tagged cell membrane marker
PH and histone H2B to identify blastomeres and follow their
cell-cycle progression. Embryos were bathed in PST-1, and indi-
vidual cells within 8- to 32-cell stage embryos were targeted with
millisecond pulses of 405 and/or 514 nm light, once the chro-
mosomes organized into a single plate (entry to metaphase).Cell 162, 403–Applying 405 nm pulses blocked the
targeted cell in metaphase (Figure 6A;
Movie S4), but cells targeted by a 405 +
514 nm rescue protocol divided normally
(Figure 6B; Movie S5). Crucially, in bothcases, neighboring cells continued mitosis unperturbed. Thus,
PST-1 can achieve reversible, optical control over MT dynamics
and its dependent processes in vivo, and can execute that
control with single-cell spatial precision.
Lastly, we examined PSTs’ control over the MT cytoskeleton
in mammalian tissue in vivo. We selected the highly water-
soluble prodrug PST-1P to avoid needing a cosolvent, aiming
at better in vivo compatibility. The cremaster muscle tissue of
living mice was superfused (Baez, 1973) for 40 min with
PST-1P, while being either illuminated at 390 nm with a low-
power LED or else kept in the dark. Then, under red light con-
ditions, animals were sacrificed and the tissue was excised,
fixed, and stained for MTs. PST-1P destroyed the MT network
under 390 nm illumination, but caused no disruptive effects in
the dark (Figure 6C; Figures S5A–S5D). This confirms the suit-
ability of PSTs for optically defined MT depolymerization in
mammalian tissue in vivo.
DISCUSSION
Biological implementations of photoswitchable small molecules
have traditionally focused on transmembrane proteins, usually
expressed in neurons, whose inherently nonlinear response
has contributed to many successful applications (Fehrentz
et al., 2011). Here, we show that photopharmacology also offers
valuable applications to intracellular targets such as the micro-
tubule cytoskeleton, which is highly conserved and funda-
mental to all eukaryotes (Dumontet and Jordan, 2010). The
PSTs embed a photoswitch inside the CDI pharmacophore,411, July 16, 2015 ª2015 Elsevier Inc. 407
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Figure 5. PST-1 Optically Controls Microtubule Dynamics in Living Cells with Full Reversibility
(A) Reversible trans4cis photoisomerization of PST-1 in cellulo by alternating phases of blue and green light causes microtubule dynamics to stop and start
again, with <1 s response time and with full reversibility (see full data in Movies S1 and S2). MDA-MB-231 cells transiently expressing EB3-mCherry were
incubated for 10 min in the dark with 10 mM PST-1 or with cosolvent control, then imaged at 561 nm under alternating phases of illuminations at 405 nm and
514 nm (images from the time-lapse sequence are shown in chronological order; scale bars, 20 mm).
(B–E) Statistical analysis of the number of EB3 comets (B), and their lifetime (C), speed (D), and total distance traveled (E) show that PST-1 treatment allows for full,
reversible optical control over microtubule dynamics in cellulo, with MT dynamics being blocked under phases of blue illumination but resuming normal behavior
under phases of green illumination. Grey bars represent data for cells illuminated but without PST-1 treatment, while colored bars represent cells illuminated and
treated with PST-1 at 10 mM (for which the color indicates the phase’s illumination wavelength). Data were assembled from u-track analysis of multiple
independent movies acquired as in (A), and are given as mean ± SEM for each phase, with phases arranged in chronological order; each phase lasted 2 min. The
bleaching of the mCherry tag over the course of the experiment reduces the automatic detection of EB3 comets by u-track, which progressively reduces the
apparent comet number determined by conservative analysis (B); for unbiased analysis consult the original data in Movies S1 and S2.generating minimal-complexity cell permeant compounds which
are straightforward to synthesize and can be applied as water-
soluble prodrugs. The PSTs have reproduced the MT disrupting,
cytostatic, and cytotoxic effects of their CDI isosteres (Bhatta-
charyya et al., 2008) through in vitro, in cellulo, and in vivo as-
says, with the novel advantage that PSTs can spatially and
temporally target these effects with full reversibility.
PSTs can exploit visible light trans4cis photoswitching, com-
bined with spontaneous cis/trans relaxation, to create steep408 Cell 162, 403–411, July 16, 2015 ª2015 Elsevier Inc.cis/trans spatiotemporal gradients even in vivo. Since the
cis-PSTs are two orders of magnitude more potent than the
trans-PSTs, this allows them to apply their strong bioactivity in
a highly localized fashion. The PSTs’ temporal specificity on
the order of seconds, and spatial specificity down to at least
the single-cell level, enable a variety of precise and fully revers-
ible studies which are inaccessible to the current MT inhibitors.
We envision that finely localized light delivery, possibly com-
bined with substitution patterns that give faster spontaneous
AB
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Figure 6. PSTs Optically Control MT Struc-
ture and Function In Vivo
(A and B) PSTs achieve fully reversible optical
control over mitosis within a living organism, with
single-cell spatial precision (see full data in Movies
S4 and S5). C. elegans embryos expressing
mCherry::H2B and mCherry::PH were bathed in
40 mMPST-1, and a single cell in each embryo was
illuminated at either 405 nm (blue ROI, toxic regime)
or 405 + 514 nm (green ROI, rescue protocol). Cells
illuminated by the toxic regime showed mitotic ar-
rest (stationary chromosomes marked with red ar-
rows), while in cells exposed to the rescue protocol,
chromosomes continued to segregate (yellow ar-
rows); neighboring cells continued mitosis unper-
turbed. Scale bars, 10 mm; time is shown relative to
chromosomeorganization into themetaphaseplate
(start of illumination); two z-slices are given in (B)
at t = 8 min, as the cells of interest had moved to
distinct focal planes; see also Figures S4B–S4G.
(C) PST-1P applied in living mouse tissue gives
complete MT disruption under 390 nm light, but
has no effects in the dark. The cremaster muscle
in live C57BL/6 mice was superfused with 50 mM
PST-1P or with PBS (‘‘ctrl’’) for 40 min while dark
conditions or 390 nm were applied. Muscle was
then excised, fixed, and stained for a-tubulin
(yellow) and nuclei (red). 3D-rendered z-stacks of
total thickness 30 mm are shown; scale bars,
15 mm. See also Figure S5.cis/trans relaxation, may also allow PSTs to achieve subcellu-
larly localized MT inhibition. The reversibility of the PSTs’ bioac-
tivity allows quick recovery of normal MT function after PST
treatment, so studies may establish not only the short-term con-
sequences of inhibiting MT-dependent processes, but also their
long-term effects on the whole organism. We therefore expect
that PSTs will prove useful tools for spatiotemporally precise
research into a range of MT-dependent processes, including
intracellular transport, synaptic plasticity, cell division, motility,
invasion, and angiogenesis, revealing new insights in cellular
and developmental biology as well as in vivo physiology.
Considering medical applications, we anticipate that the cis-
PSTs will share many of the features that especially suit CA4 to
tumor chemotherapy (Tron et al., 2006), in addition to the
cytotoxic and antimitotic properties we have demonstrated.
Crucially, however, the PSTs may avoid the therapeutically
limiting side effects of the current MT inhibitors, as PSTs applied
globally may be activated locally by precise illumination in vivo.
This will benefit from the light delivery methods developed over
decades of research in photodynamic therapy, and more
recently, in optogenetics (Grossweiner, 2005; Ibsen et al.,
2013). It may be possible to use dual wavelength illuminations
to actively restrain the cis form inside a protective ‘‘belt
zone’’ (Figure S1F). We also anticipate that the PSTs’ sponta-
neous cis/trans relaxation, on the scale of minutes, can
passively reduce systemic exposure to bioactive cis-PSTs.
PSTs may thus be used to deliver stronger on-target effects
than can be achieved with the current, globally active MT inhib-
itors, while simultaneously reducing the accompanying side
effects. Therefore we envision that PSTs will not only prove to
be useful tools for cell biology, but also promise to delivermore efficient cancer chemotherapy, using the spatiotemporal
precision of photopharmacology.
EXPERIMENTAL PROCEDURES
Chemical Synthesis and Photocharacterizations
PSTs were synthesized and characterized by standard chemical methods. The
UV-visible absorption spectra of the cis and trans isomers were determined by
HPLC-UV-Vis. A monochromator was used to perform trans4cis isomeriza-
tions in vitro, with readout by UV-Vis spectroscopy. UV-Vis spectroscopy
was used to monitor spontaneous cis/trans relaxation. Full design, synthe-
sis, and photocharacterization of the PSTs is detailed in the Supplemental
Information.
Cell Culture Assays
MDA-MB-231, Jurkat, HEK293T, and HeLa cell lines were maintained under
standard cell culture conditions. PSTs were applied using aminimum of cosol-
vent, typically 2% acetonitrile for 100 mM PST. Cells were incubated in light-
proof boxes, either in the dark (trans-PSTs) or with pulsed illuminations using
a home-made ‘‘Disco’’ LED lighting system (cis-PSTs and rescue protocol).
The Disco uses an Arduino microcomputer to operate arrays of LEDs that
can be placed under or over well plates to illuminate them during an
experiment. Typically, 10–30well plates per assaywere illuminated using inde-
pendent pulse timings and wavelengths (Figure S6). Crystal violet staining
(Saotome et al., 1989) and MTT assay (Cushman et al., 1991) were performed
according to standard protocols. Nuclear fragmentation, cell-cycle analysis
and propidium iodide exclusion assays were performed using flow cytometry
analysis according to standard procedures (Nicoletti et al., 1991). Full details
of cell culture assays and a guide to build and run the Disco LED system are
given in the Supplemental Information.
In Vitro Tubulin Radioligand Binding Competition Assay
Scintillation proximity assay was performed as described (Tahir et al., 2000),
with the Disco LED system used to apply 390 nm light pulses to assay cis-
PST-1 (see Supplemental Information for further details).Cell 162, 403–411, July 16, 2015 ª2015 Elsevier Inc. 409
In Vitro Tubulin Polymerization Assay
Tubulin polymerization assay was performed as described (Lin et al., 1988),
with a monochromator used to apply 390 nm light to assay the cis-PSTs
(see Supplemental Information for further details).
Fixed and Live Cell Imaging by Confocal Microscopy
For fixed cell imaging, MDA-MB-231 cells were incubated with PST under illu-
mination by the Disco system, then washed with extraction buffer to remove
monomeric and dimeric tubulin subunits, fixedwith glutaraldehyde, and immu-
nostained for a-tubulin by standard methods, then imaged with a Zeiss LSM
510 Meta confocal microscope. For video microscopy, HeLa cells were tran-
siently transfected with EB3-mCherry plasmid using the jetPRIME reagent.
Following the addition of PST-1, EB3-mCherry was imaged at 561 nm at a
rate of 17 frames per minute using an UltraVIEW VOX spinning-disk confocal
microscope, while cells were exposed to alternating phases of pulsed
photoisomerization illuminations (one 100 ms pulse every 3.53 s) using lasers
at 405 nm and 514 nm, with each phase lasting for 2 min (see Supplemental
Information for further details). EB3 comets were tracked and analyzed with
the MATLAB software u-track (Applegate et al., 2011); data for corresponding
photoisomerization phases were averaged across multiple independent
experiments to yield the final statistics.
C. elegans Video Microscopy
The C. elegans fluorescent strain ANA090 was cultured using standard proto-
cols and maintained at 25C. RNAi against perm-1 was performed by feeding
ANA090 L4 larva on HT115 bacteria for 24 hr according to standard protocol
(Carvalho et al., 2011), then embryos were mounted with 40 mM PST-1
and imaged at 561 nm using a Zeiss LSM 710 confocal microscope, using
405 nm and 514 nm laser ROI illuminations to achieve PST photoisomeriza-
tions within selected cells (see Supplemental Information for further details).
Mouse Cremaster Muscle Experiment
Male C57BL/6mice at the age of 10–12weeks were prepared for microsurgery
of the cremaster muscle as previously described (Baez, 1973), and 50 mM
PST-1Pwas added to the superfusion solution. For 40min, animals were either
kept in the dark, or else had the pelvic region illuminated by a 390 nm LED
with milliwatt-range light output. Animals were then sacrificed, and the tissue
was excised, immunostained, and imaged on a Leica SP5 confocal micro-
scope following standard procedures (Rehberg et al., 2010) (see Supplemental
Information for further details). Mouse experiments were performed according
to German legislation for the protection of animals and approved by the
Regierung von Oberbayern, Mu¨nchen, Germany, with protocols approved
under permits 55.2-1-54-2532-110-12.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and five movies and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2015.06.049.
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